Morgan Stanley Tcr2 Therapeutics Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.0 - $1.62 $108,995 - $176,571	108,995 Added 234.93%	155,390 $233,000
Q4 2022 Feb 14, 2023	SELL	$0.83 - $1.44 $22,287 - $38,668	-26,853 Reduced 36.66%	46,395 $46,000
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $141,983 - $286,256	-76,335 Reduced 51.03%	73,248 $131,000
Q2 2022 Oct 27, 2022	SELL	$2.11 - $2.94 $290,798 - $405,187	-137,819 Reduced 47.95%	149,583 $434,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $290,798 - $405,187	-137,819 Reduced 47.95%	149,583 $434,000
Q1 2022 Oct 27, 2022	BUY	$2.4 - $4.71 $330,765 - $649,127	137,819 Added 92.14%	287,402 $794,000
Q1 2022 May 13, 2022	SELL	$2.4 - $4.71 $386,227 - $757,970	-160,928 Reduced 35.89%	287,402 $794,000
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $1.46 Million - $2.66 Million	318,953 Added 246.53%	448,330 $2.09 Million
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $1.09 Million - $2.37 Million	129,377 New	129,377 $1.1 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.